{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:51:20Z","timestamp":1792507880887,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11912-020-0871-6","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T16:02:50Z","timestamp":1579536170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Nausea and Vomiting: a Palliative Care Imperative"],"prefix":"10.1007","volume":"22","author":[{"given":"Rita J.","family":"Wickham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"issue":"1","key":"871_CR1","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.jpainsymman.2013.10.009","volume":"47","author":"PH Hawley","year":"2014","unstructured":"Hawley PH. The bow tie model of 21st century palliative care. J Pain Symptom Manag. 2014;47(1):e2\u20135. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.10.009.","journal-title":"J Pain Symptom Manag"},{"issue":"10","key":"871_CR2","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1089\/jpm.2018.0622","volume":"22","author":"Brian Li","year":"2019","unstructured":"Li B, Mah K, Swami N, et al. Symptom assessment in patients with advanced cancer: are the most severe symptoms the most bothersome? J Palliat Med. 2019. https:\/\/doi.org\/10.1089\/jpm.2018.0622.","journal-title":"Journal of Palliative Medicine"},{"key":"871_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/cercor\/bhs073","volume":"23","author":"V Napadow","year":"2013","unstructured":"\u2022 Napadow V, Sheehan JD, Kim J, et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex. 2013;23:806\u201313. https:\/\/doi.org\/10.1093\/cercor\/bhs073. Functional MRI study investigated brain regions involved in temporal evolution of nausea; greater nausea intensity was associated sustained activation in a broader network of interoceptive, limbic, somatosensory, and cognitive processing areas in the human brain.","journal-title":"Cereb Cortex"},{"key":"871_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.autneu.2016.07.003","volume":"202","author":"CD Balaban","year":"2017","unstructured":"Balaban CD, Yates BJ. What is nausea? A historical analysis of changing views. Auton Neurosci. 2017;202:5\u201317. https:\/\/doi.org\/10.1016\/j.autneu.2016.07.003.","journal-title":"Auton Neurosci"},{"key":"871_CR5","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Wickham RJ. Revisiting the physiology of nausea and vomiting\u2014challenging the paradigm. Support Care Cancer. Online first: 06 August 2019. https:\/\/doi.org\/10.1007\/s00520. Current, in-depth review of differing physiological mechanisms, neural pathways, transmitters and receptors for vomiting and for nausea; new proposed paradigm for nausea and for vomiting.","DOI":"10.1007\/s00520"},{"key":"871_CR6","doi-asserted-by":"publisher","first-page":"R573","DOI":"10.1016\/j.cub.2017.05.010","volume":"27","author":"N Gogolla","year":"2017","unstructured":"Gogolla N. The insular cortex. Curr Biol. 2017;27:R573\u201391. https:\/\/doi.org\/10.1016\/j.cub.2017.05.010.","journal-title":"Curr Biol"},{"key":"871_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nrn2555","volume":"10","author":"AD Craig","year":"2009","unstructured":"Craig AD. How do you feel \u2014 now? The anterior insula and human awareness. Nat Rev Neurosci. 2009;10:59\u201370. https:\/\/doi.org\/10.1038\/nrn2555.","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"871_CR8","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s00520-018-4623-1","volume":"27","author":"Signe Harder","year":"2019","unstructured":"Harder S, Herrstedt J, Isaksen J, et al. The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. Support Care Cancer. 2019. https:\/\/doi.org\/10.1007\/s00520-018-4623-1.","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"871_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1756283X15618131","volume":"9","author":"P Singh","year":"2016","unstructured":"Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol. 2016;9(1):98\u2013112. https:\/\/doi.org\/10.1177\/1756283X15618131.","journal-title":"Ther Adv Gastroenterol"},{"issue":"1","key":"871_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/jpm.2018.0260","volume":"22","author":"TA Sande","year":"2019","unstructured":"Sande TA, Laird BJ, Fallon MT. The management of opioid-induced nausea and vomiting in patients with cancer: a systematic review. J Palliat Med. 2019;22(1):90\u20137. https:\/\/doi.org\/10.1089\/jpm.2018.0260.","journal-title":"J Palliat Med"},{"key":"871_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/CIA.S13109","volume":"6","author":"P Glare","year":"2011","unstructured":"Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243\u201359. https:\/\/doi.org\/10.2147\/CIA.S13109.","journal-title":"Clin Interv Aging"},{"key":"871_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-016-3371-3","volume":"25","author":"D Walsh","year":"2017","unstructured":"Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 updated MASCC\/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 2017;25:333\u201340. https:\/\/doi.org\/10.1007\/s00520-016-3371-3.","journal-title":"Support Care Cancer"},{"key":"871_CR13","doi-asserted-by":"publisher","first-page":"h6249","DOI":"10.1136\/bmj.h6249","volume":"351","author":"E Collis","year":"2015","unstructured":"Collis E, Mather H. Nausea and vomiting in palliative care. BMJ. 2015;351:h6249. https:\/\/doi.org\/10.1136\/bmj.h6249.","journal-title":"BMJ."},{"issue":"3","key":"871_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.amsu.2015.07.018","volume":"4","author":"HJM Ferguson","year":"2015","unstructured":"Ferguson HJM, Ferguson CI, Speakman J, Ismail T. Management of intestinal obstruction in advanced malignancy. Ann Med Surg (Lond). 2015;4(3):264\u201370. https:\/\/doi.org\/10.1016\/j.amsu.2015.07.018.","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"871_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jpainsymman.2013.08.022","volume":"8","author":"G Laval","year":"2014","unstructured":"\u2022 Laval G, Marcelin-Benazech B, Guirimand F, et al. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manag. 2014;8(1):75\u201391. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.08.022. French Health Authority (HAS) evidence-based clinical guidelines for the diagnosis and management of bowel obstruction.","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"871_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3949\/ccjm.78a.10052","volume":"78","author":"A Soriano","year":"2011","unstructured":"Soriano A, Davis MP. Malignant bowel obstruction: individualized treatment near the end of life. Cleve Clin J Med. 2011;78(3):197\u2013206. https:\/\/doi.org\/10.3949\/ccjm.78a.10052.","journal-title":"Cleve Clin J Med"},{"issue":"6","key":"871_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jpainsymman.2016.05.032","volume":"52","author":"GP Obita","year":"2016","unstructured":"Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW. Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manag. 2016;52(6):901\u201319. https:\/\/doi.org\/10.1016\/j.jpainsymman.2016.05.032.","journal-title":"J Pain Symptom Manag"},{"key":"871_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12957-015-0455-3","volume":"13","author":"X Peng","year":"2015","unstructured":"Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 2015;13:50. https:\/\/doi.org\/10.1186\/s12957-015-0455-3.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"871_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/bmb\/ldq031","volume":"96","author":"DG Harris","year":"2010","unstructured":"Harris DG. Nausea and vomiting in advanced cancer. Br Med Bull. 2010;96(1):175\u201385. https:\/\/doi.org\/10.1093\/bmb\/ldq031.","journal-title":"Br Med Bull"},{"issue":"9","key":"871_CR20","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1089\/jpm.2013.0610","volume":"17","author":"M Agar","year":"2014","unstructured":"To THM, Agar M, Yates P, Currow DC. Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors. J Palliat Med. 2014;17(9):1032\u20136. https:\/\/doi.org\/10.1089\/jpm.2013.0610.","journal-title":"J Palliat Med"},{"issue":"6","key":"871_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.5272\/jimab.2014206.539","volume":"20","author":"M Valkova","year":"2014","unstructured":"Valkova M, Stamenov B, Peychinska D, et al. Metoclopramide-induced extrapyramidal signs and symptoms \u2013 brief review of literature and case report. J IMAB. 2014;20(6):539\u201341. https:\/\/doi.org\/10.5272\/jimab.2014206.539.","journal-title":"J IMAB"},{"key":"871_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ejphar.2013.10.010","volume":"722","author":"P Gordon","year":"2014","unstructured":"Gordon P, LeGrand SB, Walsh D. Nausea and vomiting in advanced cancer. Eur J Pharmacol. 2014;722:187\u201391. https:\/\/doi.org\/10.1016\/j.ejphar.2013.10.010.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"871_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.4103\/IJPC.IJPC_30_18","volume":"24","author":"N Gupta","year":"2018","unstructured":"Gupta N, Puri S, Kumar V, Garg R, Bharati SJ, Mishra S, et al. Olanzapine in the treatment of refractory nausea and vomiting in palliative care settings. Indian J Palliat Care. 2018;24(3):372\u20134. https:\/\/doi.org\/10.4103\/IJPC.IJPC_30_18.","journal-title":"Indian J Palliat Care"},{"key":"871_CR24","unstructured":"Lewis K, O\u2019Day CS. Dystonic reactions. In: StatPearls (nternet). Updated3\/23\/ 2019. Treasure Island: StatPearls Publishing. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531466\/?report=classic. Accessed 11 Sept 2019."},{"issue":"3","key":"871_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.psc.2016.04.003","volume":"39","author":"SN Caroff","year":"2016","unstructured":"Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin North Am. 2016;39(3):391\u2013411. https:\/\/doi.org\/10.1016\/j.psc.2016.04.003.","journal-title":"Psychiatr Clin North Am"},{"issue":"5","key":"871_CR26","first-page":"296","volume":"46","author":"RO Tachere","year":"2017","unstructured":"Tachere RO, Modirrousta M. Beyond anxiety and agitation: a clinical approach to akathisia. Aust Fam Physician. 2017;46(5):296\u20138.","journal-title":"Aust Fam Physician"},{"issue":"6","key":"871_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/JCP.0000000000000412","volume":"35","author":"M Poyurovsky","year":"2015","unstructured":"Poyurovsky M, Weizman A. Treatment of antipsychotic-related akathisia revisited. The role of serotonin 2A receptor antagonists. J Clin Psychopharmacol. 2015;35(6):711\u20134. https:\/\/doi.org\/10.1097\/JCP.0000000000000412.","journal-title":"J Clin Psychopharmacol"},{"key":"871_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1191\/0269216304pm881oa","volume":"18","author":"J Vella-Brincat","year":"2004","unstructured":"Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med. 2004;18:195\u2013201. https:\/\/doi.org\/10.1191\/0269216304pm881oa.","journal-title":"Palliat Med"},{"issue":"4","key":"871_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1049909111423094","volume":"29","author":"E Prommer","year":"2012","unstructured":"Prommer E. Role of haloperidol in palliative medicine: an update. Am J Hosp Palliat Care. 2012;29(4):295\u2013301. https:\/\/doi.org\/10.1177\/1049909111423094.","journal-title":"Am J Hosp Palliat Care"},{"key":"871_CR30","doi-asserted-by":"publisher","unstructured":"Murray-Brown F, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients (review). Cochrane Database Syst Rev. 2015;(11). https:\/\/doi.org\/10.1002\/14651858.CD006271.pub3.","DOI":"10.1002\/14651858.CD006271.pub3"},{"issue":"1","key":"871_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/jpm.2017.0159","volume":"21","author":"M Digges","year":"2018","unstructured":"Digges M, Hussein A, Wilcock A, et al. Pharmacovigilance in hospice\/palliative care: net effect of haloperidol for nausea or vomiting. J Palliat Med. 2018;21(1):37\u201343. https:\/\/doi.org\/10.1089\/jpm.2017.0159.","journal-title":"J Palliat Med"},{"issue":"1","key":"871_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/jpm.2015.0224","volume":"19","author":"D MacKintosh","year":"2016","unstructured":"MacKintosh D. Olanzapine in the management of difficult to control nausea and vomiting in a palliative care population: a case series. J Palliat Med. 2016;19(1):87\u201390. https:\/\/doi.org\/10.1089\/jpm.2015.0224.","journal-title":"J Palliat Med"},{"key":"871_CR33","unstructured":"\u2022 Credible Meds. 2019. Available at https:\/\/crediblemeds.org\/healthcare-providers\/. This site, which is frequently updated, lists evidence-based prescription and recreational (cocaine) drugs having the potential to increase the QT interval and induce Torsades de pointes."},{"key":"871_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1750-1172-3-18","volume":"3","author":"L Crotti","year":"2008","unstructured":"Crotti L, Celano G, Dagradi F, Schwartz PJ. Congenital long QT syndrome. Orphanet J Rare Dis. 2008;3:18. https:\/\/doi.org\/10.1186\/1750-1172-3-18.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"871_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2354.2006.00760.x","volume":"16","author":"RE Kast","year":"2007","unstructured":"Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care. 2007l;16(4):351\u20134. https:\/\/doi.org\/10.1111\/j.1365-2354.2006.00760.x.","journal-title":"Eur J Cancer Care"},{"issue":"2","key":"871_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87\u201396. https:\/\/doi.org\/10.1016\/0893-133X(94)00129-N.","journal-title":"Neuropsychopharmacology."},{"issue":"6","key":"871_CR37","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391","volume":"23","author":"SD Passik","year":"2002","unstructured":"Passik SD, Lundberg J, Kirsh KL. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23(6):526\u201332. https:\/\/doi.org\/10.1016\/S0885-3924(02)00391.","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"871_CR38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jpainsymman.2011.10.023","volume":"44","author":"K Kaneishi","year":"2012","unstructured":"Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag. 2012;44(4):604\u20137. https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.10.023.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"871_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(05)70182-0","volume":"6","author":"MA Raji","year":"2005","unstructured":"Raji MA. Management of chemotherapy-induced side-effects. Lancet Oncol. 2005;6(6):357. https:\/\/doi.org\/10.1016\/S1470-2045(05)70182-0.","journal-title":"Lancet Oncol"},{"issue":"4","key":"871_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.psym.2016.02.012","volume":"57","author":"ND Allen","year":"2016","unstructured":"Allen ND, Leung JG, Betcher HK, Borreggine KL, Hosker DK, Minton BA, et al. Mirtazapine for symptomatic relief on a psychiatric consultation service: a case series. Psychosomatics. 2016;57(4):409\u201313. https:\/\/doi.org\/10.1016\/j.psym.2016.02.012.","journal-title":"Psychosomatics."},{"issue":"3","key":"871_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SAK Anttila","year":"2001","unstructured":"Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249\u201364. https:\/\/doi.org\/10.1111\/j.1527-3458.2001.tb00198.x.","journal-title":"CNS Drug Rev"},{"key":"871_CR42","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2147\/DDDT.S125743","volume":"11","author":"M Malamood","year":"2017","unstructured":"Malamood M, Roberts A, Kataria R, Parkman HP, Schey R. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017;11:1035\u201341. https:\/\/doi.org\/10.2147\/DDDT.S125743.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"871_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4103\/IJPC.IJPC_17_17","volume":"23","author":"N Kumar","year":"2017","unstructured":"Kumar N, Barai S, Gambhir S, Rastogi N. Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia. Indian J Palliat Care. 2017;23(3):335\u20137. https:\/\/doi.org\/10.4103\/IJPC.IJPC_17_17.","journal-title":"Indian J Palliat Care"},{"issue":"2","key":"871_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1049909118797283","volume":"36","author":"LR Jaward","year":"2019","unstructured":"Jaward LR, O\u2019Neil TA, Marks A, Smith MA. Differences adverse effect profiles of corticosteroids in palliative care patients. Am J Hosp Palliat Med. 2019;36(2):158\u201368. https:\/\/doi.org\/10.1177\/1049909118797283.","journal-title":"Am J Hosp Palliat Med"},{"key":"871_CR45","doi-asserted-by":"publisher","unstructured":"Vayne-Bossert P, Haywood A, Good P, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database Syst Rev. 2017;(7). https:\/\/doi.org\/10.1002\/14651858.CD012002.pub2.","DOI":"10.1002\/14651858.CD012002.pub2"},{"key":"871_CR46","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1007\/s00520-018-4339-2","volume":"26","author":"Y Hatano","year":"2018","unstructured":"Hatano Y, Matsuoka H, Lam L, Currow DC. Side effects of corticosteroids in patients with advanced cancer: a systematic review. Support Care Cancer. 2018;26:3979\u201383. https:\/\/doi.org\/10.1007\/s00520-018-4339-2.","journal-title":"Support Care Cancer"},{"key":"871_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1472-684X-12-2","volume":"12","author":"I Dietz","year":"2013","unstructured":"Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care. 2013;12:2. https:\/\/doi.org\/10.1186\/1472-684X-12-2.","journal-title":"BMC Palliat Care"},{"key":"871_CR48","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/0006-2952(79)90198-9","volume":"28","author":"PM Laduron","year":"1979","unstructured":"Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol. 1979;28:2161\u20135. https:\/\/doi.org\/10.1016\/0006-2952(79)90198-9.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"871_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1345\/aph.18003","volume":"33","author":"JA Barone","year":"1999","unstructured":"Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429\u201340.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"871_CR50","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1177\/2050640618799153","volume":"6","author":"S Bor","year":"2018","unstructured":"Bor S, Demir M, Ozdemi O, Yuksel K. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. United European Gastroenterol J. 2018v;6(9):1331\u201346. https:\/\/doi.org\/10.1177\/2050640618799153.","journal-title":"United European Gastroenterol J"},{"issue":"9","key":"871_CR51","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/MCG.0000000000001183","volume":"53","author":"Justin Field","year":"2019","unstructured":"Field J, Wasilewski M, Bhuta R, et al. Effect of chronic domperidone use on QT interval: a large single center study. J Clin Gastroenterol. 2019. https:\/\/doi.org\/10.1097\/MCG.0000000000001183.","journal-title":"Journal of Clinical Gastroenterology"},{"key":"871_CR52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/MAJ.0000000000000439","volume":"349","author":"A Ortiz","year":"2015","unstructured":"Ortiz A, Cooper CJ, Alvarez A, Gomez Y, Sarosiek I, McCallum R. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349:421\u20134. https:\/\/doi.org\/10.1097\/MAJ.0000000000000439.","journal-title":"Am J Med Sci"},{"issue":"5","key":"871_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0885-3924(97)00229-7","volume":"14","author":"F Gonzalez-Rosales","year":"1997","unstructured":"Gonzalez-Rosales F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manag. 1997;14(5):311\u20134. https:\/\/doi.org\/10.1016\/S0885-3924(97)00229-7.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"871_CR54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00105-005-1063","volume":"57","author":"M Zutt","year":"2006","unstructured":"Zutt M, H\u00e4n\u00dfle H, Emmert S, et al. Dronabinol zur supportiven Therapie metastasierter maligner Melanome mit Lebermetastasen (Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases). Hautarzt. 2006;57(5):423\u20137. https:\/\/doi.org\/10.1007\/s00105-005-1063.","journal-title":"Hautarzt"},{"issue":"1","key":"871_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1049909113504240","volume":"32","author":"SL Hernandez","year":"2015","unstructured":"Hernandez SL, Sheyner I, Stover KT, Stewart JT. Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. Am J Hosp Palliat Care. 2015;32(1):5\u20137. https:\/\/doi.org\/10.1177\/1049909113504240.","journal-title":"Am J Hosp Palliat Care"},{"issue":"3","key":"871_CR56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.tips.2006.01.010","volume":"27","author":"V Di Marzo","year":"2006","unstructured":"Di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci. 2006;27(3):134\u201340. https:\/\/doi.org\/10.1016\/j.tips.2006.01.010.","journal-title":"Trends Pharmacol Sci"},{"key":"871_CR57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1139\/cjpp-2016-0346","volume":"95","author":"Y Lu","year":"2017","unstructured":"Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017;95:311\u201327. https:\/\/doi.org\/10.1139\/cjpp-2016-0346.","journal-title":"Can J Physiol Pharmacol"},{"key":"871_CR58","doi-asserted-by":"publisher","DOI":"10.17226\/24625","volume-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017","unstructured":"\u2022\u2022 National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017. https:\/\/doi.org\/10.17226\/24625. A comprehensive, in-depth review of existing evidence and summary recommendations regarding health effects of cannabis and cannabis-derived products, as well as potential therapeutic uses. This work was implemented to help advance research and inform public health decisions."},{"key":"871_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejim.2018.01.023","volume":"49","author":"LB-L Schleider","year":"2018","unstructured":"\u2022 Schleider LB-L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37\u201343. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.023. Analysis of routinely collected data regarding the benefits and burdens of medical marijuana, prescribed to almost 3000 cancer patients with symptomatic disease who were followed over 2 years. This article also describes the processes of physician prescription and nurse selection (with patient) of particular cannabis strains, dose escalation, and patient and family teaching.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"871_CR60","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.3747\/co.23.3099","volume":"23","author":"DI Abrams","year":"2016","unstructured":"Abrams DI. Integrating cannabis into clinical cancer care. Curr Oncol. 2016;23(2):S8\u2013S14. https:\/\/doi.org\/10.3747\/co.23.3099.","journal-title":"Curr Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0871-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-020-0871-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0871-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:37:18Z","timestamp":1611016638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-020-0871-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-0871-6","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"20 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Rita J. Wickham has received compensation from Helsinn Healthcare SA and Insys Therapeutics for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"1"}}